<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>AmitisGen TECH Dev Group</PublisherName>
				<JournalTitle>Personalized and Precision Medicine Journal</JournalTitle>
				<Issn>3115-7874</Issn>
				<Volume>7</Volume>
				<Issue>25</Issue>
				<PubDate PubStatus="epublish">
					<Year>2022</Year>
					<Month>06</Month>
					<Day>20</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Alternatives to Antibiotics GOAL: ELEVATING Antibiotic Resistance During the Post-COVID Period</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>36</FirstPage>
			<LastPage>42</LastPage>
			<ELocationID EIdType="pii">253553</ELocationID>
			
<ELocationID EIdType="doi">10.22034/pmj.2022.253553</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Saber</FirstName>
					<LastName>Kabiri-Samani</LastName>
<Affiliation>Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Mandana</FirstName>
					<LastName>Sanatgaran</LastName>
<Affiliation>Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Nastaran</FirstName>
					<LastName>Shojaei-Barjoei</LastName>
<Affiliation>Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.</Affiliation>
<Identifier Source="ORCID">0009-0006-5466-2343</Identifier>

</Author>
<Author>
					<FirstName>Reyhaneh</FirstName>
					<LastName>Moosavi</LastName>
<Affiliation>Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Parinaz</FirstName>
					<LastName>Shaqaqi</LastName>
<Affiliation>Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Hamidreza</FirstName>
					<LastName>Kabiri</LastName>
<Affiliation>Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran; Sina Borna Aria (SABA) Co., Ltd, Research and Development Center for Biotechnology, Shahrekord, Iran.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2022</Year>
					<Month>02</Month>
					<Day>05</Day>
				</PubDate>
			</History>
		<Abstract>The COVID-19 outbreak offers an unmatched chance to take advantage of personalized medicine&#039;s benefits for the protection, detection, medication, monitoring, and administration of a fresh public health crisis. Antibiotics, which were formerly regarded as miracle cures and among the most difficult life-saving discoveries of the twentieth century, are now posing a hazard to society as a result of overuse and abuse. Antimicrobial resistance (AMR) is a widespread issue that is becoming worse, and the current COVID-19 pandemic might make things even worse. It has been shown that a significant portion of Covid-19 patients gets secondary microbiological infections. The medical industry is now facing difficulties because of this. As a result, several non-antibiotic techniques have been sought, and their processes have been examined, to slow the spread of AMR.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Antibacterial resistance</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">COVID-19</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Phyto-therapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Phage-therapy</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.pmjournal.ir/article_253553_2a4b37475b17972d17ae2862334977f0.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
